Patent: 9,707,154
✉ Email this page to a colleague
Summary for Patent: 9,707,154
Title: | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
Abstract: | The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LUCENTIS.RTM. (ranibizumab), BEXSERO.RTM. (meningococcal group B vaccine [rDNA, component, adsorbed]), AIN457 (secukinumab) or RELAXIN.RTM. (serelaxin). |
Inventor(s): | Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY) |
Assignee: | Corning Incorporated (Corning, NY) |
Application Number: | 14/259,270 |
Patent Claims: | see list of patent claims |
Details for Patent 9,707,154
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2033-04-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2033-04-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2033-04-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2033-04-24 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2033-04-24 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | For Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2033-04-24 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 05/28/2021 | ⤷ Try a Trial | 2033-04-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |